IFLR is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement


7,012 results7,012 results
6
of
351
Deal Highlights
0 results0 results
Deal Name Deal Date Firm Name Jurisdiction Deal Type Lawyer Names Client Names Client Role
There are no results
By Firm
0 results0 results
Firm Name Jurisdiction Total Deals Deals (Last 12 Months)
There are no results
Eric Romba explains why digital finance regulation has become a live business priority – and why Fieldfisher is using it as a foundation in Berlin
Among top hires, Orrick added a Kirkland & Ellis capital markets duo, Paul Weiss brought in NY capital markets partners, while King & Spalding, Hogan Lovells Cadwalader and Lowenstein Sandler expanded their structured finance and securities benches
Daniel Burbeary, appointed to lead the City office in February, discusses specialist growth, client demand and building the firm’s London presence
Among top hires, Akin continues its Chicago build-out, while Latham, Reed Smith and Vinson & Elkins expanded their infrastructure, PE, corporate and regulatory benches
Defence finance is moving from specialist lending into infrastructure-style investment as governments seek bankable routes to private capital
Among top moves, Freshfields and Baker McKenzie strengthened their corporate benches, while Sidley added a former Ashurst partner in Hong Kong
Additions at King & Spalding, Latham, White & Case and Norton Rose Fulbright spanned fund finance, capital markets, M&A, energy and data centres, while Orrick added a Willkie partner to lead French project finance
Additions from Clifford Chance, Mayer Brown, Akin and Freshfields headlined a week that also included an M&A hire for Paul Weiss and Cleary’s hire of a PE-focused debt finance partner
Sponsored

Sponsored

  • Sponsored by Bär & Karrer
    Nxera Pharma Co. Ltd, listed on the Tokio Stock Exchange, has entered into an exclusive licensing agreement with Santhera Pharmaceuticals under which Nxera will commercialize the drug AGAMREE® in Japan, South Korea, Australia and New Zealand. Concurrently, Nxera invests in SIX-listed Santhera Pharmaceuticals Holding AG.
  • Sponsored by Bär & Karrer
    In connection with a carve-out process, the Ortlinghaus Group sold its EM+H Division, which encompasses among others the production and sale of electromagnetic brakes and clutches as well as pneumatic toothed clutches and other trade goods to Stüwe Switzerland AG, a group company of Stüwe GmbH & Co. KG.
  • Sponsored by Zepos & Yannopoulos
    Zepos & Yannopoulos continues its longstanding presence and active involvement in landmark transactions in the food & beverage retail sector in Greece. We advised ANEDIK Kritikos on the sale of 100% of ANEDIK Kritikos S.A. to Diamantis Masoutis S.A., paving the way for the creation of a new national retail group, subject to approval by the Hellenic Competition Commission.